MAPK9 and steatosis: Moreover, our previous study demonstrated that JNK-IN-5A, a selective JNK2 and JNK3 inhibitor (Angell et al., 2007; Cerbone et al., 2012), effectively decreased fat accumulation and steatosis-related protein expression in an in vitro steatosis model (Kim et al., 2023).